BPC
EIGR

Banque Pictet & Cie’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Banque Pictet & Cie’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-33
Closed -$155K – 533
2014
Q3 		$155K Sell
33
-1
-3% -$5.28K ﹤0.01% 439
2014
Q2 		$244K Buy
34
+5
+17% +$25K 0.01% 401
2014
Q1 		$154K Buy
+29
New +$137K ﹤0.01% 407

Other funds holding EIGR

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Banque Pictet & Cie's EIGR Position: Q4 2014 in Review

Banque Pictet & Cie sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2014, closing a stake of 33 shares — an estimated $155K sold.

Banque Pictet & Cie first reported a position in EIGR in Q1 2014 and held it in 3 quarters. The position peaked at $244K in Q2 2014. 66 funds tracked by Wall St. Rank hold EIGR as of Q4 2014.

  • Banque Pictet & Cie reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Banque Pictet & Cie sold 33 Eiger BioPharmaceuticals, Inc. shares in Q4 2014, an estimated $155K.
  • Banque Pictet & Cie first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Banque Pictet & Cie's Eiger BioPharmaceuticals, Inc. position peaked at $244K in Q2 2014.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2014.

Based on Banque Pictet & Cie's 13F filing for Q4 2014, filed 12 Feb 2015.